Key Benefits:
Director General of the National Drug and Health Products Safety Agency,
Vu le Public Health Codeincluding articles L. 5311-1 et seq. and R. 5322-14;
Vu la Act No. 2011-2012 of 29 December 2011 on strengthening the health safety of the drug and health products;
Vu le Decree No. 2012-597 of 27 April 2012 the National Drug Safety Agency and Health Products;
Having regard to the decree of 1 August 2014 appointing the Director General of the National Agency for the Safety of Medicine and Health Products - M. MARTIN (Dominique);
In light of amended decision DG No. 2012-237 of 24 September 2012 organizing the National Drug Safety Agency and Health Products;
In light of amended decision DG No. 2012-238 of 24 September 2012 appointing the National Drug and Health Products Safety Agency;
In light of amended decision DG No. 2014-231 of September 1, 2014, with delegation of signature at the National Drug and Health Products Safety Agency,
Decides:
The IV of section 12 of decision DG No. 2014-231 of September 1, 2014 referred to above is amended as follows:
"IV. - Permanent delegation is given to Ms. CACHET (Mélanie), Head of the Pharmaceutical Inspection Unit and Counter Fraud 1 and to Ms. WAYSBAUM (Virginie), Head of the Pharmaceutical Inspection Unit and Counter Fraud 2 to sign, on behalf of the Director General of the National Agency for Drug Safety and Health Products, all decisions within the limits of the duties of the two Pharmaceutical Trade Points. »
This decision, effective 1 September 2015, will be published in the Official Journal of the French Republic.
Done on August 21, 2015.
D. Martin
